Patents by Inventor Glenn M. Swartz, Jr.

Glenn M. Swartz, Jr. has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7524865
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.
    Type: Grant
    Filed: July 21, 2004
    Date of Patent: April 28, 2009
    Assignee: Celgene Corporation
    Inventors: Robert J. D'Amato, Shawn J. Green, Glenn M. Swartz, Jr., Jamshed H. Shah, John Madsen
  • Patent number: 7112602
    Abstract: The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(?)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.
    Type: Grant
    Filed: December 9, 2003
    Date of Patent: September 26, 2006
    Assignee: The Children's Medical Center Corporation
    Inventors: Robert J. D'Amato, Shawn J. Green, John W. Madsen, William Fogler, Glenn M. Swartz, Jr., Adonia E. Papathanassiu, Jamshed H. Shah
  • Patent number: 6673828
    Abstract: The invention provides new and useful analogs of 2-phthalimidinoglutaric acid. These analogs include DL-2-methyl-2-phthalimidinoglutaric acid and hydroxylated analogs of 2-phthalimidinoglutaric. The invention also provides processes for making these analogs. The invention also provides the two individual enantiomers of DL-2-methyl-2-phthalimidinoglutaric acid, (R)-(+)-2-methyl-2-phthalimidinoglutaric acid and (S)-(−)-2-methyl-2-phthalimidinoglutaric acid, and processes for separating these individual enantiomers from the racemate. Further, the invention provides methods for inhibiting angiogenesis and treating angiogenesis-associated diseases, including cancer and macular degeneration, by administering one or more of these compounds.
    Type: Grant
    Filed: May 11, 1999
    Date of Patent: January 6, 2004
    Assignee: Children's Medical Center Corporation
    Inventors: Shawn J. Green, Glenn M. Swartz, Jr., Jamshed H. Shah, John Madsen, Adonia E. Papathanassiu, William Fogler
  • Patent number: 6518298
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprises the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.
    Type: Grant
    Filed: February 20, 2001
    Date of Patent: February 11, 2003
    Assignee: Entremed, Inc.
    Inventors: Shawn J. Green, Glenn M. Swartz, Jr., Jamshed H. Shah, John Madsen, Robert J. D'Amato
  • Patent number: 6228879
    Abstract: The present invention comprises a group of compounds that effectively inhibit angiogenesis. More specifically, the invention comprise the compound EM-138 and its use in the inhibition of angiogenesis and treatment of angiogenesis associate diseases, including the inhibition of tumor growth and metastasis.
    Type: Grant
    Filed: March 26, 1999
    Date of Patent: May 8, 2001
    Assignee: The Children's Medical Center
    Inventors: Shawn J. Green, Glenn M. Swartz, Jr., Jamshed H. Shah, John Madsen, Robert J. D'Amato
  • Patent number: 6224902
    Abstract: The present invention relates to immunoreactive vaccine compositions for immunizing humans or animals against sterols, such as cholesterol and its derivatives, and their use in methods for reducing the serum cholesterol levels of the immunized individuals and to retard or reduce the severity of artherosclerosis or artherosclerosis plaques caused by ingestion of dietary cholesterol.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: May 1, 2001
    Assignee: EntreMed, Inc.
    Inventors: Carl R. Alving, Julie Kenner, Glenn M. Swartz, Jr., John W. Madsen
  • Patent number: 5753260
    Abstract: The present invention relates to immunoreactive compositions and methods for immunizing humans or animals against sterols, such as cholesterol and its derivatives, and their use in methods for reducing the serum cholesterol levels of the immunized individuals and to retard or reduce the severity of atherosclerosis or atherosclerosis plaques caused by ingestion of dietary cholesterol. Another embodiment of the present invention encompasses ergosterol or ergosterol derivative compositions useful for the treatment or prevention of fungal infection, and methods of use thereof. Yet another aspect of the invention is dairy products containing anti-ergosterol antibodies produced by dairy animals immunized against ergosterol according to the present invention and methods of making thereof. A further aspect of the invention is a diagnostic assay for determining whether a human or animal has a fungal infection.
    Type: Grant
    Filed: April 14, 1995
    Date of Patent: May 19, 1998
    Assignee: EntreMed, Inc.
    Inventors: Carl R. Alving, Julie Kenner, Glenn M. Swartz, Jr., John W. Madsen
  • Patent number: 4885256
    Abstract: Monoclonal antibodies which demonstrate specific reactivity to cholesterol and methods for the detection of high levels of cholesterol by contacting biological specimens containing cholesterol with the monoclonal antibodies and measuring the formation of antigen-antibody complexes by immunosorbent assay.
    Type: Grant
    Filed: June 17, 1986
    Date of Patent: December 5, 1989
    Assignee: The United States of America as represented by the United States Army
    Inventors: Carl R. Alving, Glenn M. Swartz, Jr.